Limits...
Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data.

Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, Nakayama M, Matsuzaka M, Hattori M, Sugiyama H, Oze I, Tanaka R, Nomura E, Nishino Y, Matsuda T, Ioka A, Tsukuma H, Nakayama T, J-CANSIS Research Gro - Cancer Sci. (2014)

Bottom Line: We estimated the 10-year relative survival of patients who were followed-up between 2002 and 2006 using period analysis.Conditional 5-year survival for most cancer sites increased according to years, whereas those for liver cancer and multiple myeloma did not increase.It is important for patients and clinicians to report these relevant figures using population-based data.

View Article: PubMed Central - PubMed

Affiliation: Center for Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

Show MeSH

Related in: MedlinePlus

Conditional 5-year survival for male (a) and female (b) cancer patients in Japan followed-up in 2002–2006. (c) Conditional 5-year survival for childhood and adolescent and young adult (AYA) cancer patients followed-up in 2002–2006. ALL, acute lymphoblastic leukemia; CNS, central nervous system; ML, malignant lymphoma; MM, multiple myeloma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462379&req=5

fig02: Conditional 5-year survival for male (a) and female (b) cancer patients in Japan followed-up in 2002–2006. (c) Conditional 5-year survival for childhood and adolescent and young adult (AYA) cancer patients followed-up in 2002–2006. ALL, acute lymphoblastic leukemia; CNS, central nervous system; ML, malignant lymphoma; MM, multiple myeloma.

Mentions: Conditional survival showed different patterns according to cancer site (Fig. 2a,b, Table 1, and Table S4.1–4.3 in detail). Most cancer sites, such as stomach, colorectum gallbladder, and kidney, showed that after surviving 2–3 years post diagnosis, the conditional 5-year survival approached 100%. Conditional survival of liver cancer and multiple myeloma patients did not increase; even 5 years post diagnosis, conditional 5-year survival was <50%. Prostate and breast cancer patients achieved high 5-year survival from the initial phase after diagnosis; however, survival among those with conditional 5-year survival did not increase. This means that a small proportion of those cancer patients continued to die after diagnosis. For thyroid and skin cancer, 5-year survival at diagnosis was approximately 90%, and conditional 5-year survival of survivors some years after diagnosis was approaching 100%. This means that patients of those cancers generally did not die from those cancers for a long time.


Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data.

Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, Nakayama M, Matsuzaka M, Hattori M, Sugiyama H, Oze I, Tanaka R, Nomura E, Nishino Y, Matsuda T, Ioka A, Tsukuma H, Nakayama T, J-CANSIS Research Gro - Cancer Sci. (2014)

Conditional 5-year survival for male (a) and female (b) cancer patients in Japan followed-up in 2002–2006. (c) Conditional 5-year survival for childhood and adolescent and young adult (AYA) cancer patients followed-up in 2002–2006. ALL, acute lymphoblastic leukemia; CNS, central nervous system; ML, malignant lymphoma; MM, multiple myeloma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462379&req=5

fig02: Conditional 5-year survival for male (a) and female (b) cancer patients in Japan followed-up in 2002–2006. (c) Conditional 5-year survival for childhood and adolescent and young adult (AYA) cancer patients followed-up in 2002–2006. ALL, acute lymphoblastic leukemia; CNS, central nervous system; ML, malignant lymphoma; MM, multiple myeloma.
Mentions: Conditional survival showed different patterns according to cancer site (Fig. 2a,b, Table 1, and Table S4.1–4.3 in detail). Most cancer sites, such as stomach, colorectum gallbladder, and kidney, showed that after surviving 2–3 years post diagnosis, the conditional 5-year survival approached 100%. Conditional survival of liver cancer and multiple myeloma patients did not increase; even 5 years post diagnosis, conditional 5-year survival was <50%. Prostate and breast cancer patients achieved high 5-year survival from the initial phase after diagnosis; however, survival among those with conditional 5-year survival did not increase. This means that a small proportion of those cancer patients continued to die after diagnosis. For thyroid and skin cancer, 5-year survival at diagnosis was approximately 90%, and conditional 5-year survival of survivors some years after diagnosis was approaching 100%. This means that patients of those cancers generally did not die from those cancers for a long time.

Bottom Line: We estimated the 10-year relative survival of patients who were followed-up between 2002 and 2006 using period analysis.Conditional 5-year survival for most cancer sites increased according to years, whereas those for liver cancer and multiple myeloma did not increase.It is important for patients and clinicians to report these relevant figures using population-based data.

View Article: PubMed Central - PubMed

Affiliation: Center for Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.

Show MeSH
Related in: MedlinePlus